R01CA266600

Explore and Target the Epigenetic Vulnerability of Pax3-Foxo1-Driven Rhabdomyosarcoma - Abstract

The genetic abnormalities that drive tumorigenesis are usually coupled with epigenetic alterations, such as aberrant histone lysine methylations due to deregulation of histone methyltransferases and histone lysine demethylases (KDMs). Our long-term goal is to investigate the mechanism by which oncogenic transcription factors "hijack" KDMs in tumorigenesis and disease progression, and develop new therapies to block the functions of these oncoproteins by targeting KDMs.

Rhabdomyosarcoma (RMS) is a devastating soft tissue cancer in children and adolescent young adults. The alveolar RMS (ARMS) is a more aggressive subtype, with a higher rate of metastasis. ARMS is primarily driven by the pathognomonic fusion oncoprotein Pax3-Foxo1 or its variant Pax7-Foxo1 through chromosomal translocations of t(2;13)(q35;q14) or t(1;13)(p36;q14). Despite the fact that current treatment modalities have steadily improved survival of low-risk RMS patients, the outcome for fusion-positive ARMS patients with metastasis remains dismal. Even for patients with favorable outcomes, the aggressive chemotherapy and radiotherapy may lead to long-term adverse effects as children may be particularly vulnerable to long-term toxicity. These clinical challenges underscore a pressing need to identify new therapeutic targets and develop better therapies for these patients.

However, one obstacle is much less is known about vulnerabilities that arise in transformed cells by Pax3-Foxo1 that could be exploited therapeutically. In this application, we will investigate the functional impact of KDM4 in tumorigenesis driven by Pax3-Foxo1 (Aim 1); dissect the molecular mechanism of KDM4 inhibition on Pax3-Foxo1-driven ARMS (Aim 2), and translate KDM4 inhibitors into novel therapeutic approaches for Pax3-Foxo1 positive ARMS (Aim 3). This innovative study integrates multiple approaches to identify and validate new therapeutic targets and explore small molecules to dually inhibit oncoproteins in the context of a disease that is driven by an undruggable fusion oncoprotein. The proposed research will be impactful for its translational relevance for the treatment of children with high-risk RMS and have the potential to shed new light on the molecular mechanism of Pax3-Foxo1-driven ARMS.

St. Jude Children's Research Hospital

NOT APPLICABLE

93.395 - Cancer Treatment Research

National Cancer Institute (NCI) [HHS - NIH]

Memphis, Tennessee 38105 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 393% from $691,425 to $3,408,725.